eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 90 blog entries.
13 11, 2017

Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference

2017-11-13T13:13:47+00:00

Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference PALO ALTO, Calif. – November 13, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate update at Jefferies 2017 Healthcare Conference on Thursday, November [...]

Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference 2017-11-13T13:13:47+00:00
9 11, 2017

Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results

2017-11-09T13:15:05+00:00

Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results Clinical Results Planned in Each of Four Orphan Disease Programs by 4Q 2018 Cash Runway Extends Through Mid-2019 PALO ALTO, Calif., November 9, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for [...]

Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results 2017-11-09T13:15:05+00:00
6 11, 2017

Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences

2017-11-06T13:14:37+00:00

Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences PALO ALTO, Calif. – November 6, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will participate and present in three upcoming investor conferences. Jefferies 2017 London Healthcare Conference, [...]

Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences 2017-11-06T13:14:37+00:00
31 10, 2017

Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter’s Option to Purchase Additional Shares

2017-10-31T21:11:35+00:00

Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter’s Option to Purchase Additional Shares PALO ALTO, Calif., October 31, 2017 /PR Newswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the closing [...]

Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter’s Option to Purchase Additional Shares 2017-10-31T21:11:35+00:00
27 10, 2017

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock

2017-10-27T15:17:14+00:00

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock PALO ALTO, Calif., October 27, 2017 /PR Newswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the pricing of its underwritten public offering of 1,854,749 shares of its common [...]

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock 2017-10-27T15:17:14+00:00
26 10, 2017

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock

2017-10-26T21:05:24+00:00

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PALO ALTO, Calif., October 26, 2017 /PR Newswire/ – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its common [...]

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock 2017-10-26T21:05:24+00:00
24 10, 2017

Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) Meeting

2017-10-24T20:16:50+00:00

Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) Meeting PALO ALTO, Calif., October 23, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced positive interim 24-week data with pegylated interferon lambda (Lambda) in the Phase [...]

Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) Meeting 2017-10-24T20:16:50+00:00
2 10, 2017

Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting

2017-10-02T13:37:55+00:00

Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting PALO ALTO, Calif., October 2, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that two abstracts will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Washington DC, October 20 to [...]

Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting 2017-10-02T13:37:55+00:00
18 09, 2017

Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors

2017-09-18T14:31:19+00:00

Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors - Company Advancing Multiple Programs in Orphan Disease Pipeline PALO ALTO, Calif., September 18, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Evan Loh, MD to [...]

Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors 2017-09-18T14:31:19+00:00
5 09, 2017

Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

2017-09-05T13:52:48+00:00

Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PALO ALTO, Calif., Sept 5, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan designation for pegylated [...]

Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 2017-09-05T13:52:48+00:00